Celltrion Pharm Reports Record Quarterly Operating Profit Driven by Broad Business Growth

Celltrion Pharm has achieved its highest-ever quarterly operating profit in the second quarter, fueled by robust performance across all its business segments. The company announced on August 4 that its consolidated revenue reached 153.3 billion won, with an operating profit of 19.3 billion won.

This significant financial achievement represents a substantial year-on-year increase, with revenue growing by 16.8% and operating profit by 24.4% compared to the second quarter of the previous year. The company attributes this success to the balanced growth of its chemical drug division, its biosimilar products, and its contract manufacturing organization (CMO) services.

The strong results underscore Celltrion Pharm's expanding market presence and its effective strategy in diverse pharmaceutical sectors. The company's consistent growth trajectory indicates a positive outlook for its continued development and profitability.